エーザイ、抗がん剤「タズベリク(R)錠200mg」（一般名：タゼメトスタット臭化水素酸塩）を日本においてEZH2遺伝子変異陽性の濾胞性リンパ腫に係る効能効果で新発売 Eisai Aug 16, 2021 09:00 JST Read More
エーザイ、「レンビマ(R)」と「キイトルーダ(R)」の併用療法による成人の進行性腎細胞がん一次治療に関する承認を米国FDAより取得 Eisai Aug 12, 2021 09:00 JST Read More
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC) Eisai Aug 12, 2021 08:31 HKT/SGT Read More
Following Series A Financing, Scivita Medical Completes Series B Financing of Nearly RMB0.4 Billion to Accelerate the Strategic Layout of Globalization Scivita Medical Technology Co., Ltd Aug 05, 2021 12:23 JST Read More
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards Eisai Aug 05, 2021 10:45 HKT/SGT Read More
Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures Eisai Aug 02, 2021 11:24 HKT/SGT Read More
エーザイとバイオジェン、アルツハイマー病の初めてのリアルワールド観察臨床第IV相試験となるADUHELM ICARE AD-USの試験デザインをアルツハイマー病協会国際会議2021において発表 Eisai Jul 30, 2021 10:00 JST Read More
エーザイとバイオジェン、Lecanemab（BAN2401）の臨床効果についてアルツハイマー病協会国際会議2021（AAIC2021）のLate Breakingとして発表 Eisai Jul 30, 2021 10:00 JST Read More
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401) Eisai Jul 30, 2021 09:07 HKT/SGT Read More
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021 Eisai Jul 30, 2021 08:24 HKT/SGT Read More
Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment Eisai Jul 29, 2021 16:34 HKT/SGT Read More
バイオジェンとエーザイ、ADUHELM(TM)の最新データをアルツハイマー病協会国際会議2021（AAIC2021）において発表 Eisai Jul 27, 2021 10:00 JST Read More
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021 Eisai Jul 27, 2021 08:00 HKT/SGT Read More
エーザイ、「レンビマ(R)」（レンバチニブ）と「キイトルーダ(R)」（ペムブロリズマブ）の併用療法について進行性子宮内膜がんに係る承認を米国FDAより取得 Eisai Jul 26, 2021 09:00 JST Read More
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma Eisai Jul 23, 2021 08:17 HKT/SGT Read More
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021 Eisai Jul 21, 2021 09:34 HKT/SGT Read More
